Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Benefit-risk analysis of health benefits of routine childhood immunisation against the excess risk of SARS-CoV-2 infections during the COVID-19 pandemic in Africa

View ORCID ProfileKaja Abbas, View ORCID ProfileSimon R Procter, View ORCID ProfileKevin van Zandvoort, Andrew Clark, View ORCID ProfileSebastian Funk, LSHTM CMMID CMMID COVID-19 Working Group, Tewodaj Mengistu, Dan Hogan, Emily Dansereau, View ORCID ProfileMark Jit, View ORCID ProfileStefan Flasche
doi: https://doi.org/10.1101/2020.05.19.20106278
Kaja Abbas
1London School of Hygiene & Tropical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kaja Abbas
  • For correspondence: kaja.abbas@lshtm.ac.uk
Simon R Procter
1London School of Hygiene & Tropical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Simon R Procter
Kevin van Zandvoort
1London School of Hygiene & Tropical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin van Zandvoort
Andrew Clark
1London School of Hygiene & Tropical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Funk
1London School of Hygiene & Tropical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sebastian Funk
1London School of Hygiene & Tropical Medicine
Tewodaj Mengistu
2Gavi, the Vaccine Alliance
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Hogan
2Gavi, the Vaccine Alliance
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Dansereau
3Bill & Melinda Gates Foundation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Jit
1London School of Hygiene & Tropical Medicine
4Public Health England
5University of Hong Kong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark Jit
Stefan Flasche
1London School of Hygiene & Tropical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefan Flasche
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background National immunisation programmes globally are at risk of suspension due to the severe health system constraints and physical distancing measures in place to mitigate the ongoing COVID-19 pandemic. Our aim is to compare the health benefits of sustaining routine childhood immunisation in Africa against the risk of acquiring SARS-CoV-2 infections through visiting routine vaccination service delivery points.

Methods We used two scenarios to approximate the child deaths that may be caused by immunisation coverage reductions during COVID-19 outbreaks. First, we used previously reported country-specific child mortality impact estimates of childhood immunisation for diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, pneumococcal, rotavirus, measles, meningitis A, rubella, and yellow fever (DTP3, HepB3, Hib3, PCV3, RotaC, MCV1, MCV2, MenA, RCV, YFV) to approximate the future deaths averted before completing five years of age by routine childhood vaccination during a 6-month COVID-19 risk period without catch-up campaigns. Second, we analysed an alternative scenario that approximates the health benefits of sustaining routine childhood immunisation to only the child deaths averted from measles outbreaks during the COVID-19 risk period. The excess number of infections due to additional SARS-CoV-2 exposure during immunisation visits assumes that contact reducing interventions flatten the outbreak curve during the COVID-19 risk period, that 60% of the population will have been infected by the end of that period, that children can be infected by either vaccinators or during transport and that upon child infection the whole household would be infected. Country specific household age structure estimates and age dependent infection fatality rates are then applied to calculate the number of deaths attributable to the vaccination clinic visits. We present benefit-risk ratios for routine childhood immunisation alongside 95% uncertainty range estimates from probabilistic sensitivity analysis.

Findings For every one excess COVID-19 death attributable to SARS-CoV-2 infections acquired during routine vaccination clinic visits, there could be 84 (14-267) deaths in children prevented by sustaining routine childhood immunisation in Africa. The benefit-risk ratio for the vaccinated children, siblings, parents or adult care-givers, and older adults in the households of vaccinated children are 85,000 (4,900 - 546,000), 75,000 (4,400 - 483,000), 769 (148 - 2,700), and 96 (14 - 307) respectively. In the alternative scenario that approximates the health benefits to only the child deaths averted from measles outbreaks, the benefit-risk ratio to the households of vaccinated children is 3 (0 - 10) under these highly conservative assumptions and if the risk to only the vaccinated children is considered, the benefit-risk ratio is 3,000 (182 - 21,000).

Interpretation Our analysis suggests that the health benefits of deaths prevented by sustaining routine childhood immunisation in Africa far outweighs the excess risk of COVID-19 deaths associated with vaccination clinic visits, especially for the vaccinated children. However, there are other factors that must be considered for strategic decision making to sustain routine childhood immunisation in African countries during the COVID-19 pandemic. These include logistical constraints of vaccine supply chain problems caused by the COVID-19 pandemic, reallocation of immunisation providers to other prioritised health services, healthcare staff shortages caused by SARS-CoV-2 infections among the staff, decreased demand for vaccination arising from community reluctance to visit vaccination clinics for fear of contracting SARS-CoV-2 infections, and infection risk to healthcare staff providing immunisation services as well as to their households and onward SARS-CoV-2 transmission into the wider community.

Funding Gavi, the Vaccine Alliance and Bill & Melinda Gates Foundation (OPP1157270)

Evidence before the study National immunisation programmes globally are at risk of disruption due to the severe health system constraints caused by the ongoing COVID-19 pandemic and the physical distancing measures to mitigate the outbreak. The decrease in vaccination coverage increases the proportion of susceptible children at risk of increased morbidity and mortality from vaccine-preventable disease outbreaks. Outbreaks of vaccine preventable disease have been observed during previous interruptions to routine immunisation services during an ongoing infectious disease epidemic, such as during the 2013-2016 Ebola outbreak in West Africa, when most health resources were shifted towards the Ebola response which led to decreasing vaccination coverage and consequently outbreaks of measles and other vaccine-preventable diseases.

Added value of this study We estimated the benefit-risk ratio by comparing the deaths prevented by sustaining routine childhood immunisation for diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, pneumococcal, rotavirus, measles, meningitis A, rubella, and yellow fever vaccines with the excess COVID-19 deaths associated with vaccination clinic visits. The benefit of routine childhood immunization programmes in all the 54 countries of Africa is higher than the COVID-19 risk associated with these vaccination clinic visits.

Implications of all the available evidence Routine childhood immunisation programmes should be safeguarded for continued service delivery and prioritised for the prevention of infectious diseases, as logistically possible, as part of delivering essential health services during the COVID-19 pandemic in Africa. The current immunisation service models will require adaptation, including physical distancing measures, personal protective equipment, and good hygiene practices for infection control at the vaccination clinics, and have to be complemented by new immunisation service models for sustaining routine childhood immunisation in the African countries during the COVID-19 risk period.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NA

Funding Statement

Gavi, the Vaccine Alliance and Bill & Melinda Gates Foundation (OPP1157270)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All data were from secondary sources in the public domain, and ethics approval was thereby not required.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • stefan.flasche{at}lshtm.ac.uk

Data Availability

The program code and data for the benefit-risk analysis conducted in this study is accessible on GitHub (https://github.com/vaccine-impact/epi_covid).

https://github.com/vaccine-impact/epi_covid

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted June 24, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Benefit-risk analysis of health benefits of routine childhood immunisation against the excess risk of SARS-CoV-2 infections during the COVID-19 pandemic in Africa
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Benefit-risk analysis of health benefits of routine childhood immunisation against the excess risk of SARS-CoV-2 infections during the COVID-19 pandemic in Africa
Kaja Abbas, Simon R Procter, Kevin van Zandvoort, Andrew Clark, Sebastian Funk, LSHTM CMMID CMMID COVID-19 Working Group, Tewodaj Mengistu, Dan Hogan, Emily Dansereau, Mark Jit, Stefan Flasche
medRxiv 2020.05.19.20106278; doi: https://doi.org/10.1101/2020.05.19.20106278
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Benefit-risk analysis of health benefits of routine childhood immunisation against the excess risk of SARS-CoV-2 infections during the COVID-19 pandemic in Africa
Kaja Abbas, Simon R Procter, Kevin van Zandvoort, Andrew Clark, Sebastian Funk, LSHTM CMMID CMMID COVID-19 Working Group, Tewodaj Mengistu, Dan Hogan, Emily Dansereau, Mark Jit, Stefan Flasche
medRxiv 2020.05.19.20106278; doi: https://doi.org/10.1101/2020.05.19.20106278

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (419)
  • Anesthesia (97)
  • Cardiovascular Medicine (895)
  • Dentistry and Oral Medicine (166)
  • Dermatology (101)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (404)
  • Epidemiology (8756)
  • Forensic Medicine (4)
  • Gastroenterology (403)
  • Genetic and Genomic Medicine (1854)
  • Geriatric Medicine (176)
  • Health Economics (386)
  • Health Informatics (1283)
  • Health Policy (642)
  • Health Systems and Quality Improvement (489)
  • Hematology (206)
  • HIV/AIDS (388)
  • Infectious Diseases (except HIV/AIDS) (10532)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (217)
  • Neurology (1746)
  • Nursing (100)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (457)
  • Oncology (959)
  • Ophthalmology (279)
  • Orthopedics (107)
  • Otolaryngology (174)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (555)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1839)
  • Public and Global Health (3968)
  • Radiology and Imaging (650)
  • Rehabilitation Medicine and Physical Therapy (341)
  • Respiratory Medicine (532)
  • Rheumatology (214)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (165)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (79)